Yale University

EliScholar – A Digital Platform for Scholarly Publishing at Yale
Public Health Theses

School of Public Health

January 2015

The Effect Of Exercise Versus Usual Care On
Depression In Breast Cancer Survivors: The
Hormones And Exercise (hope) Study
Bridget Ann Winterhalter
Yale University, bridget.winterhalter@yale.edu

Follow this and additional works at: http://elischolar.library.yale.edu/ysphtdl
Recommended Citation
Winterhalter, Bridget Ann, "The Effect Of Exercise Versus Usual Care On Depression In Breast Cancer Survivors: The Hormones And
Exercise (hope) Study" (2015). Public Health Theses. 1325.
http://elischolar.library.yale.edu/ysphtdl/1325

This Open Access Thesis is brought to you for free and open access by the School of Public Health at EliScholar – A Digital Platform for Scholarly
Publishing at Yale. It has been accepted for inclusion in Public Health Theses by an authorized administrator of EliScholar – A Digital Platform for
Scholarly Publishing at Yale. For more information, please contact elischolar@yale.edu.

1

Bridget Winterhalter
Social and Behavioral Science
The effect of exercise versus usual care on depression in breast cancer survivors:
The Hormones and Exercise (HOPE) Study

2

The effect of exercise vs. usual care on depression in breast cancer survivors:
The Hormones and Exercise (HOPE) Study

Bridget Winterhalter1, Brenda Cartmel1,2, Melinda Irwin1,2
1. Yale School of Public Health, New Haven, CT
2. Yale Cancer Center, New Haven, CT

3
ABSTRACT
Purpose: Despite effective therapies and treatments, breast cancer survivors often suffer from
distressing side effects which may increase depressive symptomatology. Aromatase inhibitors
(AI) are widely used as adjuvant treatment in breast cancer patients, but are associated with
side effects such as joint pain that may impact quality of life. We conducted, in 121 breast
cancer survivors receiving an AI, a yearlong randomized trial of exercise versus usual care on
depressive symptomology.
Methods: Eligibility criteria included taking an AI for at least 6 months, reporting < 90 minutes
per week of exercise and no strength training, and reporting > 3 on a scale of 10 for worst joint
pain on the Brief Pain Inventory (BPI). Participants were randomly assigned to exercise (150
minutes per week of aerobic exercise and supervised strength training twice per week) or usual
care. The Centers for Epidemiological Studies: Depression Scale (CES-D) was completed at
baseline and 6- and 12 months. Intervention effects were evaluated using generalized linear
models, comparing change at 6- and 12 months.
Results: Over 12 months, a 4.7 point (36%) decline in CES-D score was seen for women
randomly assigned to exercise (n = 60) versus a 0.3-point (2%) decline among those receiving
usual care (n = 60; p <0.05). In secondary analysis, women that scored above the generally
accepted CES-D score cutoff of 16 (indicating depressive symptomatology), had a 12.6 (+2.6)
point (50%) decrease (mean+SD) in CES-D score, significantly greater than those in this
category who were assigned to usual care, 5.5 (+2.8) point decrease (29%). Women with later
stage breast cancer, those who had taken AIs for a longer period of time, and those who had
attended more supervised exercise sessions showed a greater decrease in CES-D scores
compared to their counterparts.
Conclusion: Exercise led to favorably reductions in CES-D scores in previously inactive breast
cancer survivors taking AIs. Exercise programs should be implemented for breast cancer
survivors in an effort to reduce depressive symptoms.
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INTRODUCTION
There are approximately 3.1 million breast cancer survivors in the United States, a result
in part of improved treatments.1 With survival rates increasing, researchers are increasingly
looking at side effects that affect quality of life in breast cancer survivors. Cancer survival can
be accompanied by adverse physiological and psychological side effects, such as weight
changes, decreased strength and flexibility, and depression and anxiety. 2-6
Depression is a relatively common side effect of cancer and cancer treatment and its
prevalence varies by cancer site.7 Depression is characterized by feelings of sadness,
hopelessness, changes in sleep and appetite, psychomotor retardation, and withdrawal from
social contact.7 Cancer survivors may experience fear of death, disease relapse, and body
image changes that can contribute to a reduced quality of life and impaired social and
occupational functioning. Depression in cancer survivors is often correlated to various
comorbities, such as obesity, diabetes, and the development of cardiovascular disease.8
Breast cancer survivors are at an increased risk for depression, due to the side effects of
cancer treatment. The prevalence of depression among breast cancer survivors ranges widely
from 1.5 to 46 percent, dependent on variables such as age, treatment, number of children at
home, and socioeconomic status .9 Current treatments for depression in cancer survivors
include pharmacologic interventions and psychotherapy. For many, these treatments are safe,
effective, and provide significant benefit. For others, they may have limited usefulness because
of personal, behavioral, or biological factors.7
Additionally, other breast cancer treatment-related side effects may increase depression
symptomatology. Agents such as steroids and estrogen depleting interventions, which can alter
serotonin levels, are associated with the development of depression.10 Aromatase inhibitors (AI)
are widely used as adjuvant treatment for postmenopausal women with estrogen receptorpositive breast cancer and act through estrogen depletion. Arthralgia (i.e., joint pain) is one of
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the major complaints of breast cancer patients undergoing AI treatment, and may be associated
with worse overall quality of life and psychological well-being.11
Exercise has been identified as a treatment that may provide symptom relief for
depression, as well as improve physical health outcomes in cancer survivors.12 Accumulating
evidence suggests exercise after diagnosis of cancer may improve functional capacity,
muscular strength, and reduce cancer-related fatigue. Trials of exercise among breast cancer
survivors have generally had small sample sizes and have varied widely in quality and in
specifics such as exercise prescription, time since diagnosis, and choice of patient-reported
outcomes. Recent systematic reviews and meta-analyses have reported clear benefits of
physical activity for cardiovascular fitness in breast cancer survivors, but report only generally
modest or inconsistent effects for outcomes like depression.13 No large-scale randomized
controlled trial assessing the effect of exercise on depression in breast cancer survivors, in
particular, those taking AIs, has been conducted.
We recently completed a randomized trial, the Hormones and Physical Exercise (HOPE)
Study, which examined the effect of an exercise intervention vs. usual care on AI side-effects in
breast cancer survivors. The purpose of this paper was to evaluate how the HOPE exercise
intervention vs. usual care impacted depression scores in women taking AIs and experiencing
arthralgia.
METHODS
The HOPE Study was a yearlong, randomized control trial, which evaluated the effect of
an exercise intervention vs. usual care (control) on AI side-effects. All study procedures,
including written informed consent, were approved by the Yale School of Medicine Human
Investigation Committee and Connecticut Department of Public Health and Human Investigation
Committee.
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Study Participants and Recruitment
Breast cancer survivors were recruited between June 1, 2010 and December 30, 2012
from 5 hospitals in Connecticut through the Rapid Case Ascertainment Shared Resource of the
Yale Cancer Center (RCA), a field arm of the CT Tumor Registry. Detailed recruitment methods
are described elsewhere.14
Eligible participants were physically inactive (<90 min/wk of physical activity in the past
six months and no strength training in the past year), postmenopausal women, diagnosed 0.54.0 years prior to enrollment with hormone receptor positive Stage I to III breast cancer, who
had taken an AI for at least six months prior to enrollment. Participants had to be experiencing
arthralgia for at least two months prior to enrollment that was a minimum of mild in severity,
defined as a score of at least 3 out of 10 on the worst pain item of the Brief Pain Inventory.15
Women were eligible if arthralgia started after initiation of an AI or if they had pre-existing join
pain as long as the pain or stiffness was exacerbated by AI use.
Primary Outcome Measures
Depression: Depression was assessed with the Centers for Epidemiological Studies –
Depression Scale16 (CES-D). The CES-D is a 20-item scale designed to measure current level
of depressive symptomatology, with emphasis on the affective component, depressed mood.
The 20 items are divided into four domains: Somatic Retarded Activity (7 items), Depressed
Affect (5 items), Positive Affect (4 items), and Interpersonal Affect (2 items), and 2 single items
that complete the total score.17 The possible range of scores is zero to 60, with higher scores
indicating more symptoms, weighted by frequency of occurrence during the past week.16 The
construct validity and internal consistency of the CES-D are good.17 The positive predictive
value is 54.5% for the cut-off score of 16 in head and neck cancer patients,17 which was also
used as the cutoff score for this population. A group with a high average score may be
interpreted to be “at risk” of depression or in need of treatment. The scale is a valuable tool to
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identify such high-risk groups and the relationships between depressive symptoms and other
variables.
Secondary Outcome Measures and Covariate Measures
An interviewer-administered questionnaire at the baseline visit was used to assess
disease stage, type of surgery, adjuvant therapy, and comorbidities. Stage was self-reported,
and was subsequently verified using medical records. Additionally, we collected information on
participants’ race/ethnicity, education level, time since diagnosis, time on AI, and height and
weight. Height and weight were measured at baseline, 6-, and 12 months. Participants were
weighed on a digital scale in light clothing, without shoes. Height without shoes was measured
using a stadiometer. All measurements were taken twice and averaged. Exerciser trainers
were responsible for recording attendance to the supervised exercise training sessions.
Physical activity was recorded at baseline, 6-, and 12 months, via an interviewer-administered
physical activity questionnaire, assessing the past 6 months of recreational activity including the
type, frequency, and duration of 20 activities.18
Exercise Intervention
To comply with current exercise recommendations for cancer survivors,19 the yearlong
exercise intervention was a combination of a twice-weekly supervised exercise training program
consisting of resistance and aerobic exercise (under supervision of an American College of
Sports Medicine certified cancer exercise trainer) at a local health club and additional aerobic
exercise on their own (at home or the gym), for a total of 150 min/wk of aerobic exercise.
Detailed information about the intervention protocol has been previously reported.14 Following
each exercise session, participants recorded the type of duration, and average heart rate during
exercise, in physical activity logs.20 Participants returned logs to the exercise trainers at the end
of each week. Exercise trainers also recorded attendance to the supervised exercise session.
The aerobic exercise intervention consisted primarily of brisk walking, either on a
treadmill or outside, although participants were allowed to choose other aerobic exercise
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training, such as stationary bicycling or using the elliptical machine. Exercise started at 50% of
maximal heart rate (determined from VO2 max testing) and gradually increased over the first
month to 60-80% of maximal heart rate for the duration of the study. The strength training
protocol consisted of six exercise: bench press, latissimus pull down, seated row, leg press, leg
extension, and leg curl. Each of these exercises were performed for 8-12 repetitions for three
sets. A standard progressive resistance training approach was used in which participants
progressed up to three sets per exercise over the first month of training. After two sessions
during which a participant lifted the same weight 12 times during each set, the weight was then
increased by the smallest possible increment.
Usual Care Group
Women were instructed to continue with their usual activities. Participants were not
discouraged from exercise on their own but were not given any exercise instruction. Both the
exercise and usual care groups were provided with an educational booklet prepared for the
HOPE study, which addressed breast cancer topics such as lymphedema and fatigue. These
topics were discussed monthly over the phone for the usual care group, or at an exercise
session for the exercisers. Participants in this group were called monthly by research staff to
determine AI adherence. In addition, AI adherence was assessed in the usual care group at the
monthly phone call. At the completion of 12 months, women were offered a supervised exercise
session and exercise handouts.
Statistical Analyses
Descriptive statistics were used to describe the study population based on sociodemographic and clinically relevant indicators according to study randomization. Participants
were analyzed using the intention-to-treat principle. For those women who did not have sixmonth questionnaires, the change in CES-D was imputed as 0. Generalized linear models
(GLM) were used comparing women randomized to the exercise intervention arm and women
randomized to the usual care group on depressive symptomatology. Potential covariates
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included baseline CES-D score, cancer stage, age, time since diagnosis, and time on AI. Only
14 women reported previous diagnosis of depression, and 11 of those women reported taking
antidepressants at baseline. Because of the small number, the effect was assumed to be very
small and this was not included in analysis. In looking at attendance using the average minutes
per week, a t-test was performed to analyze if changes were significant from baseline.
Owing to the relatively low CES-D score observed at baseline, secondary analyses were
conducted to determine the effect of exercise on CES-D by the baseline CES-D cutoff of 16.
We also examined effect modification by disease stage and time on AI. Analysis was performed
using SAS version 9.3 (Cary, NC). Statistical significance was set at p<0.05 using 2-sided
tests.
RESULTS
A total of 1,537 breast cancer survivors were identified through the Rapid Case
Ascertainment (RCA) Shared Resource of the Yale Cancer Center (Figure 1). Screening phone
calls were completed with 1016 women. Of these 1016 women screened, 253 women had
already stopped taking an AI because of side effects or chose not to take and AI because of
potential side effects. A total of 121 women were randomized. One woman did not complete
the baseline CES-D, and was subsequently removed from statistical analysis resulting in an
analytic sample of 120. Given funding cuts, the last 25 of the 121 women recruited were
enrolled into a 6-month rather than a 12-month trial. Thus, their study adherence and attrition is
based on 6-month data. Study attrition was low, with 58 of 61 exercisers (95%) and 49 of 60
usual care women (82%) completing 6-month measures, and 45 of 48 exercisers (94%) and 39
of 48 usual care women (81%) completing 12-month measures.
Women randomly assigned to exercise reported their exercise prospectively in daily
activity logs and reported and average 119 minutes per week of exercise, with an average of
70% of strength training sessions completed. There were no adverse events associated with
the exercise program. 14
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Baseline Characteristics
The average age of participants was 61 years (Table 1). The majority of the study
population were white (88%) and diagnosed with Stage I breast cancer (59%). A large portion
of the study participants had a lumpectomy or partial mastectomy (65%) and had an average
time between diagnosis and enrollment of 2.0 years. All baseline characteristics were similar for
both arms (p > 0.05).
Effect of Exercise on CES-D
At baseline, CES-D scores were similar in both groups (12.3+1.3 exercise group and
12.5+1.3 usual care; p = 0.89) (Table 2). Thirty-five individuals (29%) scored a 16 or greater on
the CES-D, indicating a higher level of depressive symptomatology. At the 6-month follow-up,
CES-D scores decreased by 3.5 (+0.8) points (28%) in women randomized to exercise
compared to a 0.6 (+0.8) decrease (5%) in women randomized to usual care (difference = 2.9; p
= 0.018) Table 2. Adjustment for age, time since diagnosis, time on AI, race, education, stage,
surgery, treatment, BMI, BPI, and baseline CES-D scores did not affect the results (results not
shown).
Stratified analyses examining the effect of the intervention specifically within those
participants who reported CES-D >16 scores at baseline. At baseline, 18 study participants
(15%) randomized to the exercise arm and 17 study participants (14%) randomized to the usual
care group scored at or above the generally accepted cutoff of 16, suggesting a potentially
elevated rate of depressive symptoms. In looking at those who scored at or above 16 on the
baseline CES-D, participants baseline CES-D score averaged 23.7 + 7.9 and 26.8 + 8.8 for
exercisers and usual care, respectively (p = 0.272) (Table 3). At 6 months, CES-D scores
decreased 12.06 (+2.0) points (48%) in women randomized to exercise verse 5.23 (+2.1) points
(22%) in women randomized to usual care (difference = 6.83 p=0.025).
Similar findings were observed when measuring mean difference of CES-D scores in
comparison to stage of breast cancer at diagnosis. Individuals diagnosed with stage 0 and I
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had averaged baseline CESD scores of 11.4 + 8.8 and 12.9 + 11.6 for exercisers and usual
care (p=0.39) (Table 4). Those diagnosed with later stage II or III breast cancer had averaged
baseline CESD scores of 14.9 + 11.3 and 13.6 + 9.6 (p =0.40). At 12 months, the CES-D
change among those in the exercise intervention at both earlier and later stages was
significantly greater than those in the usual care group. Furthermore, for those with later stage
breast cancer, their depressive symptom scores decreased by 6.0 points compared to those of
the same stage randomized to usual care group, whose scores increased by 1.7 (difference =
7.7; p = 0.006).
Baseline CES-D scores were comparable for participants taking an AI for less than 20
months and greater than 20 months (p = 0.781 and p = 0.558) (Table 4). Significant decreases
in CES-D scores can be seen in those have been on an AI for a longer period of time. Over 12
months, CES-D scores decreased by 5.1(+1.1) points in women randomly assigned to exercise,
versus a 2.2 (+1.2) increase in women randomly assigned to usual care (difference = 7.3; p =
<0.001). Adjusting for age, stage, race, surgery, treatment, and BMI did not affect the results.
Attendance was examined by using the median of 82 minutes per week. Twenty-nine women
averaged more than 82 minutes per week, decreased their CES-D score by 6.2 (+1.3) at 12
months, compared to the 31 women who averaged less than 82 minutes per week and loss
approximately 3.4 (+1.4) points. CES-D scores in both high and low attendance groups
decreased significantly compared to baseline (p=<0.001) (Table4). Similarly, significant
decreases in CES-D scores over time were seen for both attendance groups at the 6-month
time point.
DISCUSSION
In this exercise intervention trial in women receiving AI therapy for breast cancer, we
found depressive symptomatology decreased significantly more in those in the exercise
intervention versus usual care. Baseline scores were comparable to other published research
looking at the quality of life, using the CES-D in breast cancer survivors,9 21 22 On average,
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depression scores in women randomly assigned to exercise decreased from moderate at
baseline to mild at the end of the intervention period (ie, CES-D score of approximately
moderate score of 12 to mild score of 7). To our knowledge, this is the strongest
methodological study, given the randomized design, large sample size, and 12-month
intervention period, that has examined the effect of exercise on depression in breast cancer
survivors on AI therapy.
The largest effects of depression changes in cancer survivors have been found in those
who participated in programs in which all or majority of the exercise was supervised, as
compared with those exercising in the home.7 This suggests caution in how exercise programs
are implemented for breast cancer survivors if reduction in depression is a goal. The majority of
exercise interventions designed for cancer survivors, including HOPE, are not likely designed to
target depressive symptoms. Research has shown that duration of exercise session was not a
significant moderator of the effect of exercise on depression,7 but frequency of exercise was an
important factor, an exercise frequency of 5 times per week was reported as being significantly
more effective than 2 to 4 days of activity.23 Future research could compare the effect of a
variety of exercise intensities and varying lengths of exercise sessions on depression so that
evidence based recommendations can be made about the appropriate exercise prescription for
breast cancer survivors with regard to reducing depression.
Our study has some limitations. Participants in the HOPE study were primarily nonHispanic white, well educated, and diagnosed with Stage I breast cancer; therefore do not
constitute a representative sample of the overall population of breast cancer survivors. Women
with breast cancer who have lower socioeconomic status (SES) have an increased risk of
developing depression; with symptom burden differing by race and SES.24 Ideally future studies
will include larger numbers of breast cancer patients from ethnic minorities and those who have
low SES; giving a clearer view of potential moderator variables. Additionally, although most of
the participants were recruited from tumor registries, given the sizable time commitment, it is
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very possible that those women who elected to enroll in the study were higher functioning than
breast cancer survivors, in general. Most participants in HOPE scored within a “normal” range
on the CES-D, lower than a score of 16. In observing a significantly greater decrease in
depressive symptomatology among those in the exercise arm, future studies could use
depression symptomatology as an entry criterion.
Strengths of the HOPE study include the randomized design, high adherence to
exercise, and a focus on women experiencing arthralgia resulting from AI use. Studies looking
into AI-induced arthralgia are mostly small (<59 participants), uncontrolled, and of short
duration.14 However, depression was not the primary outcome of the HOPE trial and as a result
limited information was collected about the participant’s history of depression, ongoing
treatment for depression, length of current depressive symptoms, or additional psychologic
comorbities. With more specific information about onset, persistence, and treatment for specific
depression bouts, potential moderators could be examined in more detail.
Furthermore, a final strength of this study was a focus on a sample of women at higher
risk for depression because of treatment side effects. AIs are often well tolerated with very few
serious adverse events, but common side effects include joint pain, loss of bone mineral
density, hot flashes, night sweats, and vaginal dryness.25 These side effects are the primary
cause of discontinuation and often responsible for exacerbating depressive feelings and could
be a reason for higher baseline CES-D scores. Women in the HOPE study had reported the
side effect of arthralgia prior to enrollment. Improvement in arthralgia potentially stands as a
potential mediator of improving depression or vice versa. For instance, exercise was shown to
improve depressive symptomatology, which may in turn improve the side effect of joint pain, or
the psychological factors associated with pain. Appropriate management of AI side effects is of
critical importance for overall quality of life and to ensure adherence.
In conclusion, the HOPE exercise intervention improved depressive symptomatology as
measured by the CES-D. However, further research is necessary using a more diverse
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population and targeting at risk populations. With more women surviving breast cancer, it
becomes important to understand their experiences in survivorship and to give clinicians
treating them realistic expectations about the prevalence of psychological difficulties.
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Cases ascertained from
tumor registry
N = 1537

No physician consent
N = 144
Consent decline (n = 130)
No response (n = 14)

Physician consent given and recruitment letter mailed to participant
telling them we will call within 1 week to screen
(n = 1,393)

Call in (non-tumor
registry case)
(n = 35)

Ineligible
Not on AI
No joint pain (BPI<3)
Physical illness
Too physically active
Lives out of state
Does not speak English
Mental illness
No transportation
Not feeling well

Screened via telephone
(n = 1,016)

(n = 660)
(n = 253)
(n = 147)
(n = 89)
(n = 86)
(n = 39)
(n = 29)
(n = 7)
(n = 7)
(n = 3)

Unable to contact/screen
(n=412)
Disconnected (n = 62)
Wrong number (n = 41)
No answer (n = 26)
Busy signal (n = 3)
Voice message (n = 280)

Not interested
Not interested
No time
Unwilling/unable to
participate
Lives too far away
Gym too far
Declined/vague reason
Hang up

(n = 235)
(n = 95)
(n = 77)
(n = 22)
(n = 14)
(n = 12)
(n = 9)
(n = 6)

Randomly assigned
(n = 121)

Exercise group (n = 61)

Usual care group (n = 60)

Completed 6 months (n = 58/61;
95%)

Completed 6 months (n = 49/60;
82%)

Completed 12 months; (n = 45/48;
94%)

Completed 12 months (n = 38/48;
80%)

Fig 1. Flow of participants through Hormones and Physical Exercise study.
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Table 1. Baseline Characteristics (n=120)a
Characteristic
Age (years)
Body mass index (kg/m2)
Time on AI
Race/Ethnicity (%)
Non-Hispanic White
Hispanic
African American
Asian/Pacific Islander
American Indian
Education (%)
High school graduate
Some school after high school
College graduate +
Stage (%)
Stage 0 (in situ) and Stage I
Stage II and Stage III
Surgery (%)
Lumpectomy or partial mastectomy
Unilateral mastectomy
Bilateral mastectomy
Treatment (%)
Chemotherapy
Radiation
Chemotherapy and Radiation
Surgery Only
Time Since Diagnosis

a

Exercise (n=60)b
62.0 + 7.0
30.0 + 6.8
1.9 + 1.9

Usual Care (n=60)b
60.5 + 7.0
28.7 + 5.5
1.8 + 1.3

86.9
1.6
9.8
1.6
0.0

88.3
5.0
6.7
1.7
1.67

9.8
32.8
57.4

15.0
41.7
43.3

60.7
39.3

61.7
38.3

pc
0.245
0.275
0.888
0.846

0.290

0.909

0.796
70.5
16.4
13.1

65.0
18.3
16.7

6.6
36.1
45.9
11.5
2.7 + 3.1

8.33
40.0
35.0
16.7
3.3 + 3.9

0.633

0.303

Table values are mean + SD for continuous variables and % for categorical values.
Percentages may not sum to 100% due to rounding.
c
P-value is for t-test (continuous variables), x2 test (categorical variables), or Fisher’s exact test (cell
counts < 5).
b
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Table 2. Effect of exercise vs. usual care on depression changes at baseline, 6-, and 12 monthsa, b
Exercise
Usual Care
p-value
(n=60)
(n=60)
Baseline
12.3 (1.3)
12.5 (1.3)
0.885
6 Month
8.9 (1.1)
11.9 (1.1)
0.054
Change
-3.5 (0.8)
-0.6 (0.8)
0.018
Exercise
Usual Care
(n=45)
(n=38)
12 Month
7.9 (1.2)
12.5 (1.4)
0.011
Change
-4.7 (1.0)
0.3 (1.1)
0.001
a
Numbers are change in CES-D using least-square mean (SE)
b
Model controls for baseline CES-D score and study arm

Table 3. Mean depression scores and changes of those above and below CES-D score of 16 at baseline,
6-, and 12 months.a
Exercise (n=60)
Usual Care
P-value
(n=60)
CESD > 16
Baseline
23.7 (7.9)
26.8 (8.8)
0.272
(n=35)
6 Month
12.3 (7.7)
20.9 (11.2)
0.012
Change
-12.06 (2.0)
-5.23 (2.1)
0.025
12 Month
11.9 (9.7)
19.1 (10.3)
0.084
Change
-12.6 (2.5)
-5.5 (2.8)
0.073
CESD < 16
Baseline
7.4 (4.5)
6.9 (4.21)
0.599
(n=85)
6 Month
7.4 (5.6)
8.3 (6.6)
0.513
Change
0.1 (0.8)
1.3 (0.8)
0.308
12 Month
6.1 (5.8)
9.9 (6.4)
0.021
Change
-1.3 (1.0)
2.9 (1.0)
0.005
a
Numbers are change in CES-D using least-square mean (SE)
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Table 4: Change in CES-D Stratified by Study Variablesa
Change in
CES-D
Exercise
Intervention
LSMEAN (SE)
Stage O and I (n=75)
6 month
12 month
Stage II and III (n=45)
6 month
12 month
AI < 20 months (n= 59)
6 month
12 month
AI > 20 months (n = 59)
6 month
12 month
Attendance < 82 (n = 29)b
Min per week
6 month
12 month
Attendance > 82 (n = 31)b
Min per week
6 month
12 month
a
b

Change in
CES-D
Usual
Care
LSMEAN (SE)

p

-2.5 (1.1)
-4.0 (1.1)

-1.2 (1.1)
-0.2 (1.2)

0.370
0.027

-4.8 (1.4)
-6.0 (1.8)

0.3 (1.4)
1.7 (1.9)

0.013
0.006

-3.3 (1.2)
-4.6 (1.7)

0.1 (1.2)
-1.4 (1.8)

0.054
0.198

-4.0 (1.3)
-5.1 (1.1)

-1.0 (1.2)
2.2 (1.2)

0.097
<0.001

-3.2 (1.2)
-3.4 (1.4)

N/A
N/A

<0.001
<0.001

-4.2 (1.0)
-6.2 (1.3)

N/A
N/A

<0.001
<0.001

Numbers are change in CES-D using least-square mean (SE)
P-value is for t-test

